AU643447B2 - Novel carboxamide non-ionic contrast media - Google Patents

Novel carboxamide non-ionic contrast media Download PDF

Info

Publication number
AU643447B2
AU643447B2 AU58694/90A AU5869490A AU643447B2 AU 643447 B2 AU643447 B2 AU 643447B2 AU 58694/90 A AU58694/90 A AU 58694/90A AU 5869490 A AU5869490 A AU 5869490A AU 643447 B2 AU643447 B2 AU 643447B2
Authority
AU
Australia
Prior art keywords
carbamoyl
moles
carbon atoms
triiodo
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU58694/90A
Other versions
AU5869490A (en
Inventor
Milos Dr. Sovak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sovak Dr Milos
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU5869490A publication Critical patent/AU5869490A/en
Application granted granted Critical
Publication of AU643447B2 publication Critical patent/AU643447B2/en
Assigned to Sovak, Dr Milos reassignment Sovak, Dr Milos Alteration of Name(s) in Register under S187 Assignors: SCHERING AKTIENGESELLSCHAFT
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0433X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0452Solutions, e.g. for injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Triiodo-5-aminoisophthalamides in which the amino and one of the amide nitrogen groups are substituted are indicated. The compounds have at least two hydroxyl groups and low viscosity and osmolality. Processes for the preparation of the compounds are indicated.

Description

Oue Refs 325388 6434 7O IWORM
AUSTRALIA
Patents Act COMPLETE SPECIFICATION
(ORIGINAL)
Application Number: Lodged: Complete Specification Lodged: Accepted: Published: Priority: *Related Art: Applicant(s): 4 Schering Aktiengesellschaft Mullerstrasse 170-178 D-1000 BERLIN FEDERAL REPUBLIC OF GERMANY ARTHUR S. CAVE CO.
Patent Trade Mark Attorneys Level 10, 10 Barrack Street SYDNEY NSW 2000 Address for Service: Complete specification for the invntion entitled Complete specification for the invontion entitled "Novel carboxamide non-ionic contrast media".
0 The following statement is a full description of this invention, including the best method of performing it known to me:- 5020 I I la NOVEL CARBOXAMIDE NON-IONIC CONTRAST MEDIA
INTRODUCTION
s Technical Field 15 The field of the invention is methods of preparation and compositions for use as non-ionic contrast media.
Background Radiographic contrast media for visualization of the cardiovascular system and body cavities must have low visccsity, be highly water soluble, non-toxic, and have a high iodine content. Low viscosity is imperative for rapid delivery, to momentarily replace 25 rapidly flowing blood, such as in cardioangiography or high dose urography, or contrast enhancement in computerized tomography. To be non-toxic, the compound *ee. must be highly hydrophilic, non-ionic, and of osmolality close to the body milieu. While the nonionic monomeric media of the prior art have a reasonable biological tolerance and useful viscosity, they are hyperosmolal vis-a-vis the body milieu.
Typically, at the diagnostically useful concentration of 300 mg I/ml, they substantially exceed the physiological value of 310 mOsm. Hyperosmolality of these solutions necessarily drives water out of cells, disrupting the cellular membranes, perturbing the overall electrolytic balance, and damaging the lining of vessels or of organ cavities. Also, hyperosmolality has been shown to be one cause of vascular pain invariably elicited by hyperosmolal contrast media.
Most of the non-ionic contrast media, whether monomeric or oligomeric, are aromatic amides, with one or more polyhydroxy, lower aliphatic alkyl, and acyl subgroups bonded to nitrogen, with annular carboxamides and amino groups. The triiodinated benzene ring contains a number of functionalities in cloie spatial relationships. The prior art describes several hydroxyalkylamines attached as amides. Examples of these amines include: serinol; l-amino-2,3propanediol; N-methyl l-amino-2,3-propanediol; 15 aminotetritols; ethanolamine, diethanolamine, or S* tromethamine.
Substitution of the carboxyl groups in the 1 and 3 positions with the same hydroxyalkylamine poses a severe limitation on the design, since the substitutents practically available are either too small to solubilize the molecule, or too large to result in a solution of low viscosity (Nycomed, U.S.
4,021,481 and 3,701,771; Schering AG, U.S. 4,547,357, Bracco, U.S. 4,001,323). For this reason, improved compounds were developed where the two hydroxyalkylamines were different (Schering AG U.S. 4,364,921).
Such compounds, however, have a complex synthesis and are costly to synthesize.
Relevant Literature U.S. Patent Nos. 3,701,771, 4,001,323, 4,021,481, 4,364,921, 4,547,357 and co-pending U.S.
Application Serial No.214,663, filed July 1, 1988, are illustrative of various compounds reported as useful for non-ionic contrast media.
I
3 SUMMARY OF THE INVENTION Non-ionic contrast media are provided based on an asymmetrical triiodoisophthalic diamide, where the remaining ring position is occupied by a substituted nitrogen, one of the carboxyl groups being unsubstituted amide, and the other carboxyl groups being at least a mono-(hydroxyalkyl) substituted amide. The molecule has at least two hydroxyl groups.
DESCRIPTION OF SPECIFIC EMBODIMENTS Non-ionic contrast media are provided based on San acylamido substituted triiodoisophthalic diamide, where only one of the amide nitrogens is at least 15 monosubstituted. The compounds may be inexpensively synthesized in good yield and obtained in high purity.
The subject compounds have been found to provide low osmolality, while at the same time maintaining moderate to low viscosity.
The compounds of the subject invention will for the most part have the following Formula
CONE
2 25 I I O
R
3 CON
CONR
1
R
2
I
R4 I
I
wherein:
R
1 is hydrogen, lower alkyl or hyoroxyalkyl, wherein said alkyl group is from 1 to 6, usually 1 to 2 carbon atoms, and said hydroxyalkyl group has at least SA 0.5 hydroxyls per carbon atom and up to n-1 hydroxyl 1 4 groups, where n is the number of carbon atoms, hydroxyalkyl being of from 2 to 6, usually 2 to 4 carbon atoms;
R
2 is a mono- or polyhydroxyalkyl, of from 2 to 6, usually 2 to 4 carbon atoms, having at least one hydroxyl group and not less than n-2 and not more than n-l hydroxyl groups, where n is the number of carbon atoms;
R
3 is lower alkyl, hydroxy (lower alkyl), or lower alkoxy (lower alkyl), where alkyl is of from 1 to 6 carbon atoms, usually of from 1 to 3 carbon atoms, and alkoxyl is of from 1 to 3, usually 1 to 2, carbon atoms, with the number of oxy groups varying from 0 to 0 n-1, where n is the number of carbon atoms, or two R 3 groups may be taken together to define a bridge of from 0 to 2 carbon atoms, preferably 1 carbon atof; i.e. R stands for 3
CONH
2 I I S* (CH2)0-2-CON CONR R 2
R,
R
4 is hydrogen, lower alkyl, or mono- or polyhydroxyalkyl, where the alkyl groups and the hydroxyl groups come within the definitions as described above for analogous groups.
'The alkyl groups may be straight chain or branched, usually straight chained where carbon atoms will normally be other t.han quaternary.
4 A The alkyl residue in the mono- or polyhydroxyalkyl R, 1 and R2will usually have 2 to 6 carbon atoms, usually 2 to 4 carbon atoms. Preferably, the groups will have 1 to 5, usually 1 to 3 hydroxy groups. These hydroxy groups may be primary, secondary, or tertiary. Examples include trishydroxytnethylmethyl, hydroxyethyl, dihydroxypropyl, and tri-hydroxybutyl. Carbamides may be prepared using 3-amino-l,2-propanediol, serinol. or amino-tetritols, threitol and erythritol, either in D,E, mixture or optically pure forms, ethanolamine, or diethanolamine, or tromethamine, or derivatives thereof, where the hydroxlyl groups are reversibly protected. R 1 is #see hydrogen, or lower alkyl, preferably hydrogen or methyl. R 3 is a lower alkyl. or oxyalkyl of 1 to 6, usually 1 to 4 carbon atoms, preferably methyl, hydroxymethyl or hydroxyethyl. Also exemplified are alkoxyalkyls containing alkoxyl groups of 1 to 3 carbon atoms, preferably 1 to 2 carbon atoms, and alkyls, of from 1 to 3 carbon atoms, more particularly methoxymethyl. Alternatively, two R 3 groups are taken together to be a bond, methylene or ethylene, particularly meth~ylene. R 4 is hydrogen, alkyl or monoor polyhydroxyalkyl of f rom. 1 to 6, usually 1 to 4, carbon atoms, including methyl, ethyl, propyl, hydroxyethyl, and dihydroxypropyl.
Monomeric compounds of interest include (2-hydroxyethyl)methoxyacetamido]-2,4,6-triiodo-3-[N- (l,3,4-trihydroxybut-2-yl) ]carbaruoyl benzamide; A. 0 (2-hydroxyethyl)hydroxyacet lamido]-2,4,6-triiodo-3-fN- (2,3-dihydroxypropyl) Icarbamoyl benzamide; dihydroxypropyl) acetamido 1-2, 4, 6-t r iiodo-3- 3dihydroxypropyl) Icarbamoyl benzamide; 2,3dihydroxypropyl)glycolamidol-2, 4,6-triiodo-3-[N-(2hydroxyethyl) Icarbamoyl benzamide; trihydroxy-but-2-yl)acetamido]-2,4,6-triiodo-3-[N-(2hydroxyethyl) ]carbamoyl bexizamide; *S (methyl)glycolamido)-2,4,6-triiodo-3-[N-(1,3,4trihydroxy-erythro-but-2-yl Icarbamoyl bexizamide; and 5 5-[N-(2-hyd'roxyethyl)acetamido]-2,4,6-triiodo-3-(N- (1,3 ,4-trihydroxythreobut-2-yl) ]carbamoyl benzaside.
Dimeric compounds of interest include malonic acid bis- FK 3 N-(2, 3 -dihydroxypropyl-carbamoyl)5-carbamoyli, 2,4,6-tr iiodo-N(2,3-dihydroxypropyl); ralonic acid bis- 2, 3 -dihydroxypropyl-carbamoyl)5-carbamoY~i 2,4,6-triiodo-N-(2-hydroxyethyl)alilide; and malonic acid bis-H 3-N-(1 3 ,4-trihydroxy-but-2--YNcarbamoyl)- -2,4,6-triiodo-N-methyl anilide.
The compositions of the subject invention will have from about 50 to 52% iodine, usually about 51%, have a viscosity of a solution of 300 mg I/ml at 37°C (cps) in the range of about 4 to 5, and an osmolality of 300 mg I/ml at 37 0 C in mOsm for an aqueous solution in the range of about 275 to 400, more usually about 285 to 375, while with a pharmaceutical formulation, it will range from about 300 to 400, more usually about 325 to about 390.
The subject compositions are formulated in accordance with conventional conditions. Usually, the formulations will comprise an aqueous medium, which includes a physiologically acceptable chelated calcium salt, EDTA, a buffer to provide a pH in the range of about 6.5 to 7.5, particularly about 7, where the buffer may include tris, carbonate, citrate, or 15 combinations thereof. Other additives which may be included are bicarbonate, phosphate, etc. The chelated calcium will generally be present in from about 5 to usually about 10 mg/100 ml, while the buffer will generally be present in the amount from about 2 to mM.
*eO.
0** eg 9 9 46..
9@ 0, 6 4640 0 *s 9 Conventional reactions may be combined in a defined pathway to prepare the subject compounds.
Thus, in a subject process, the products of this invention can be prepared, for example, from the compound of Formula (II):
COX
0 2
N
/Rl
CON
R2 where R1 and R 2 are as defined previously, and X is either a lower alkyl ester or a halogen.
Compounds under general Formula (II) are prepared by reacting an hydroxyalkylamine
(NHRI,R
2 whose OH groups are protected or unprotected, with a commercially available monoester of 5-nitroisophthalic acid, followed by activation of the remaining carboxyl group. Such activation is suitably achieved when X is a halogen such as Cl, Br, I, or alkoxy with chlorine and methoxy being preferred.
The ester group of 5-nitroisophthalic acid, mono-ester is aminolyzed with the hydroxyalkylamine of general formula HNR 1
R
2 as defined above, or aminolysis can be achieved with ammonia first. The remaining carboxyl group is then activated as described above.
If the hydroxyl groups of the residue NR 1
R
2 are 15 unprotected and could be affected by the activation, they can suitably be protected by conventional means such as 0-acetylation or by isopropylidination.
The compound of general Formula (II) can be conveniently crystallized from water or lower alcohols.
After reaction with anhydrous ammonia or ammonium hydroxide, where the asymmetrical isophthaldiamide is obtained, the compound is hydrogenated, triiodinated and acylated in a conventional manner to arrive at general Formula (III):
CONH
2 L 2
III
R3COHN 0 CON R2 where R 1
R
2 and R3 are defined as above.
Reduction and iodination is typically carried out by standard methods using as catalysts, palladium on carbon or Raney nickel in water or lower alcohols, and hydrogen under low or high pressure. The resulting acid bisamide is then iodinated by known methods. The compound is then conveniently recovered as it crystallizes from the reaction mixture, washed, dried, and subjected to acylation, also following known methods. Thus, an activated acyl
R
3 CO-X, where X is halo or the same acyl group to form an anhydride, and catalyzing solvents such as pyridine, DMA, or DMF may be used.
If compounds according to Formula where R4 is other than hydrogen, are prepared, the alkylation is carried out by standard methods. Except for lower 9** g 15 alkyls which are conveniently introduced at an earlier stage of the synthesis, the reaction with hydroxyalkyl residues is carried out typically as the last step.
Such an alkylation can be carried out in a high boiling glycol solvent, such as ethylene or propylene glycol, and highly basic pH achieved with sodium methoxide, sodium hydroxide, or other inorganic or organic bases.
Alternatively, it is sometimes advantageous for the purposes of purification where side products are formed which would otherwise be difficult to remove by conventional purification methods, to maintain the presence of one carboxyl group until the latter stages of the reaction sequence, so that the compound can conveniently be dissolved in water as a salt and thereafter precipitated or reprecipitated with an inorganic acid. Preferred salts include ammonium, sodium, potassium, calcium, barium or lithium.
Such alternative process is based on the reduction, iodination and acetylation of compounds of Formula (II) (where X OH) in the manner described above to arrive at Formula (IV):
COOH
I I R l
R
3 COHN CON/
R
2
I
IV
where R 1
R
2 and R3 are defined above.
The hydroxyl groups are protected prior to activation of the carboxyl group. It is also necessary I to diacylate the anilide with R 3 CO, as this nitrogen 15 would likewise be adversely affected during carboxyl activation. The carboxyl group will be activated as described above, with the acid chloride being preferred, although mixed anhydrides may be used, e.g., t-butyloxycarbonyl. Compounds under Formula (IV) can 20 conveniently be crystallized from an aprotic solvent and reacted with ammonium hydroxide or ammonia, followed by alkylation as the last step.
Effective amidation usually requires use of either an excess of amidating base as an acid acceptor 25 or alternatively, tertiary amines, such as triethylamine, tributylamine, pyridine, or inorganic bases such as bicarbonate or carbonate.
Yet another variation of the synthetic prLAtss can be applied when undesirable side products occur.
30 Thus, alkylation of the anilide may be carried out prior to the amidation. Alkylation of the compounds under general Formula where R1, R 2 and R 3 are as defined above may be carried out by known methods as described above.
During alkylation to introduce R 4 the protecting groups R 3 CO are lost, and thus the hydroxyl groups of R 1 and R 2 (also R 4 if present) must be re-protected prior to carboxyl activation and subsequent amidation with ammonia. Acetyl groups are most often employed for this purpi Following the final step, if hydtoxyl groups are still protected, such as would be the case when alkylation is not carried out as the last step, the protecting groups may conveniently be removed by standard means such as exposure to ion exchange resins, or use of acids or bases in catalytic amounts in alcoholic or aqueous solvents.
Desalting can be accomplished by known methods. Typically, salts will be removed by ion exchange resins, either mixed-bed or in separate' columns individually containing an anionic or cationic 15 exchange resin. Alternatively, the compounds of general Formula can be absorbed on a polystyreneabsorbing neutral resin and thereafter eluted.
Following removal of the salts, the product can now be crystallized from a variety of solvents, preferably lower alcohols. Decolorization is achieved by refluxing in aqueous solution with activated charcoal.
The dimer is conveniently prepared from the benzamide, with the amino nitrogen alkylated and the remaining carbonyl group activated, chlorocarbonyl. The dibasic acid is used in activated form, particularly as the diacyl dichloride in an organic aprotic polar solvent. The ring carbon bound chlorocarbonyl is then hydroxyalkylamidated to obtain the final product.
The compounds of this invention and under general Formula are stable in aqueous solutions; they readily form supersaturated solutions which also remain stable. The solutions can be autoclaved by standard means. At diagnostically useful iodine concentrations, the compounds have osmolalities which typically are very close to the physiological values.
At the same time, the solution viscosity is low. Thus, the objective of this invention to overcome the previously recognized mutual exclusivity of the two factors, low osmolality and low viscosity, has been accomplished. As a result, the novel compounds have excellent local and systemic tolerance. The compounds hav good biological tolerance and high iodine content, particularly as compared to presently available non-ionic radiographic contrast media.
As examples of the properties of the benzamide class compounds, data were generated for the compounds (11) (Claim F) and (19) (Claim For comparison, data on prior art compounds are alio shown in Table
I.
s., also r 3 *se 4 em 4* ewe a est a t~ *t.
4 *0 vw 4 .J Ue6 d BASIC PROPERTIES OF Iodine of Molecular Weight Viscosity of 30.0 mg I/mi at 374C TABLE 1 NON-IONIC MONOMERIC X-RAY AEDIA Osmolality of 300 mg I/mi Solutions Aqueous Pharmaceut caT Solution Formulated Solln (mOsm) (mOsm) Approximate ranges i.v.LD0 gIk Male Mouse Male Rat 16-20 g 80-100 g lohexol lopamidol Iopromide Ioxilan Compound 19 (cpa) 4.7* 4.6* .4.7 650 671 607 560 365 300 314 685 704 630 588 390 326 322 16-17 16-18 14-16 16-18 14-16 11.5-12.5 12-13 11-12 12-13 13-14 15. 5-17.5 15 17 Compound 11 Compound 4:1 4.1 4.2 3.5 15.3-16.5 16 17.5 *Reportedl otbier data were generated in our laboratory .41l solutions are pharm~aceutically formulated except where stated.
13 The observed low osmolality and concurrent low toxicity was only previously achieved in non-ionic dimers, which, however, cannot be utilized in general uroangiography due to their high viscosity which, for a comparable solution concentration, is at least two times higher.
The novel compounds show an excellent general biological tolerance. Since high osmolality is the causative factor of vascular pain and a major side effect of depicting the peripheral limb vasculature (Sovak, Current Contrast Media and loxilan, Comparative Evaluation of Vascular Pain by Aversion Conditioning, Investigative Radiology, September, 1988 Supp). This is one of the major diagnostic procedures in vascular radiology. The novel compounds of this
*O*
15 invention are expected to be virtually painless in such procedures. Because of their physiochemical and pharmacological properties,, the novel compounds are suitable as water-soluble contrast media for the visualization of the urine excretory and cardiovascular systems, and body cavities and for general contrast enhancement in computerized tomography. The injectable solutions of the novel compounds can be prepared by dissolution in water and adding standard physiologicalcompatible buffers, and stabilizers such as chelating 25 agents. The compounds also are suitable for enteral So application when formulated with carriers usually employed in the pharmacopoeias. The dimers find particular use for myelograms.
For intravascular use, the compounds of this invention contain 20%-80% weight by volume, with iodine concentrations of 150 to 400 mg/ml preferred.
The following examples are offered by way of illustration and not by way of limitation.
EXPERIMENTAL
EXAMPLE 1 Amidation of acid, moriomethyl ester with (threo)-2-amino-l,3,4-butanetriol into: 5-nitro-3(N-(l,3_,4-trihydroxythreo-but-2-yl) }carbamoyl benzoic acid (2) The starting material 22.5 g, 0.1 mole) was mixed with, (threo)-2-amino-1,3,4-butanetrioI (30.25 g, 0.25 moles) and the suspension heated to 110-120 0
C
for 30 min. Complete conversion to the product was seen by TLC, and the solution was poured into 1. N hyrchoi aci (200 ml) to precipitate the product.
Ate ooig vrngt the product was filtered and washed with ice-cold water (20 ml x Drying in vacuo gave a white solid (2Z, 21.0 g, 67% yield).
*~.EXAMPLE 2 Esterification of 5-nitro-3(N-(l,3,4tr ihydroxy-threo-but-2-yl) Icarbamoyl benzoic acid with dimethyl sulfate into: "*to methyl 5-nit ro-3(N-( 1,3, 4-trihydrox threo-but-2-yi))carbamoyl benzoate (3) The title compound 15.7 g, 0.05 moles) was dissolved in 1 N sodium hydroxide solution (55 ml) and the solution 'cooled to 20 0 C. Dimethylsulfate (9.45 g, 0.,075 m6les) was added over 5 min and the pH was maintained between 8-10 by the occasional addition of N sodium hydroxide solution. The solutioi was stirred for ca. 12 hr at room temperature after which the insoluble solid was filtered off. The pasty solid was washed with cold water (50 ml x 2) and was dried In vacuo to give a powder 11.8 g, 721 yield) EXAMPLE 3 Amidation of methyl 5-nitro-3-(N-(1,3,4trihydroxy-threo-but-2-yl)}carbamoyl benzoate with ammonia into: 5-nitro-3-(N-(l,3,4trihydroxy-threo-but-2-yl)}carbamoyl benzamide (4) The ester 10.0 g, 0.0305 moles) was dissolved in methanol (50 ml) and concentrated ammonium hydroxide (20 ml, ca. 0.3 moles) was added. The suspension was heated in a sealed vessel at 50-60 0 C for 30 min when TLC indicated reaction completion. The methanol and ammonium hydroxide were removed by distillation, and were replaced by H 2 0 (50 ml). The mixture was cooled overnight, after which the insoluble product was filtered, and washed with cold water (5 ml 15 x Vacuum drying gave the white mixed amide (4, ~7.15 g, 75% yield).
.c .EXAMPLE 4 Chlorination of 5-nitroisophthalic acid, 20 aonomethyl ester with thionyl chloride into: 5-nitroisophthalic acid, monomethyl ester, monoacid chloride The title compound 225 g, 1 mole) was peo dissolved in ethyl acetate (0.5 L) and N,N-dimethyl- '25 formamide (0.1 ml) added as a catalyst. The solution was heated to 70°C and thionyl chloride (219 ml, 3 moles) added over 1.25 hr. The temperature was subsequently maintained at 70°C for 2 hr.
The thionyl chloride was codistilled with 30 et. rl acetate (200 ml x 3) and the product dissolved in hot ethyl acetate (250 ml) and precipitated with cyclohexane (1 filtered, and washed with cyclohexane (200 ml x Drying at 500C under vacuum gave a white solid 216g, 89% yield).
EXAMPLE Amidation of 5-nitroisophthalic acid, monomethyl ester mono acid chloride with aminodioxepan into: methyl 5-nitro-3-{N-(trans-2,2-dimethyl-6hydroxy-1,3-dioxepan-5-yl)}carbamoyl benzoate (6) The monoester, monochloride 100 g, 0.411 moles) was dissolved in dry tetrahydrofuran (1 L) and the solid aminodioxepan (132.8 g, 0.825 moles) was added in portions over 15 min, keeping the temperature below 25 0 C with the aid of an ice bath. Thereafter, the heterogenous mixture was allowed to stir for 30 min at room temperature, when TLC showed reaction completion.
The insoluble amine hydrochloride was filtered 15 off and the tetrahydrofuran was removed from the 0 filtrate by distillation. The residue was dissolved in ethyl acetate (400 ml) near the boiling point, and the solution allowed to stand for several days until crystallization of the product was complete. The solid was filtered off, washed with cold ethyl acetate (50 ml x 2) and dried in a vacuum oven, giving an off-white product 82.4 g, 55% yield).
EXAMPLE 6 Amidation of methyl 5-nitro-3-(N-(trans-2,2- .dimethyl-6-hydroxy-l,3-dioxepan-5-yl))carbamoyl benzoate with ammonium hydroxide into: 5-nitro-3-(N-(trans-2,2-dimethyl-6hydroxy-1,3-dioxepan-5-yl )carbamoyl benzamide (7) A Iarr pressure reactor (800 ml) was charged with the title comtound 80 g, 0.22 moles), methanol (110 ml) and 15 N ammonium hydroxide (225 ml, 3.38 moles). The reaction vessel was sealed and submerged in a water bath at 50 0 C for 2 hr, when TLC indicated complete reaction. The heterogeneous reaction mixture was mixed with H 2 0 (100 ml) and then stripped to a foam. The foam was slurried in H 2 0 (100 ml), filtered and washed two times with 50 ml H 2 0 to obtain a white solid 60.4 g, 79% yield).
EXAMPLE 7 Reduction and deprotection of 5-nitro-3-(N- (trans-2, 2-dimethyl-6-hydroxy-l, 3-dioxepanbenzamide with hydrogen and palladium on carbon and hydrochloric acid into: )-(hydrochloridle -3-(N-(1,3,4-trihydroxythreo-but-2-yl))carbamoyl benzamide (8) A Parr pressure reactor (2.0 L) was charged with the title compound 58 g, 0.16 moles), 1,N hydrochloric a, id3 (410 ml) and palladium-on-carbon Pd/C, 5.8 g, 1% Pd The reaction ve3sel was 5 connected to a hydrogenator and shaken under 50 psi hydrogen gas for 2 hr, when HPLC indicated conversion to product The palladium catalyst. was filtered and the acetone formed during deprotection was removed in vacuo at 50 0 C. The resulting clear solution 450 ml, 90% yield) was taken directly to iodination.
*but fee 0EX.AMPLE 8 Iodination of 5-amino-(hydrochloride)-3-(N- (1,3,4-rihydroxy-threo-but-2-y))carbamIoyl benzamide with'iodine monochloride into: 5-aminca-2 6-triiodo-3-{N- 4-trihydroxyz threo-but-2-yl) Icarbamoyl benzamide (9) The title compound (8j 0.14 moles) in 1 N~ hydrochloric acid (450 ml) was heated to 850C and iodine monochloride (135 ml, 0.49 moles) was added.
The reaction mixture was heated at 850C for 2 hr, when EPLC indicated that the reaction was done. The reaction mixture was cooled to 25*C and extracted 2 x cyclohexene (200 ml), 3 x dichloromethane (300 ml), and x chloroform (200 ml) until all the purple color was removed from the aqueous layer. The resulting light yellow solution was recirculated on a column containing Duolite-A340 (800 g) and Dowex 50W-X8 (266 g) resins.
The resins were flushed with E 2 0 (6 L) and the solution was concentrated to 300 ml when a white crystalline solid began crystallizing. The product was filtered to obtain a white solid 40 g, 0. 06 moles, 43% yield).
EXAMPLE 9 Acetylation of S-amino-2, 4,6-triiodo-3-(N 3, 4-trihydroxy-threo-but-2-yl) Icarbamoyl benzamide with acetic anhydride into: 5-diacetylamino-2,4,6-triiodo-3-(N-(l,3,4-' triacetoxy-threo-but-2-yl))carbamoyl benzamide The title compound 90 g, 0.14 moles) was mixed with acetic anhydride (500 ml, 4.95 moles) at 0 C, with vigorous stirring. Perchloric acid (0.36 ra. l, 0.004 moles) catalyst was added, causing the temperature to rise to 856C. The reaction mixture was stirred at 850C for 1 hr, when it became homogenous and TLC indicated reaction completion. Sodium acetate (0.33 g, 0.004 moles) was added to neutralize the *s 0 000 0 perchioric acid, and the solvent was removed to obtain .0:0 a thick brown oil. The oil was diluted with butyl acetate (200 ml) at 700C, followed by solvent .2.5 removal. The stripping procedure was repeated two times to obtaina brown foam (10, 113 g, 0.13 moles, 93% yield).
EXAMPLE Deacetylation and alkylation of 2,4, 6-triiodo-3tN- 4-triacetoxy-threo-but- 2-y1))carbamoyl benzamide (10 with sodium methoxide and 2-chloroethanol into: 2-hydroxyethylacetahi% o) 4, 6-triiodo-3- 1,3, 4-trihydroxy-threo-but- 2-yl))carbamoyl benzamide (11) The title compound (10, 113 g, 0.13 moles) was dissolved in methanol (500ml) to which was added sodium methoxide (55 g, 0.25 moles) at 50 0 C. After hr, HPLC indicated the deacetylation was complete and the solution was neutralized with Dowex 50 W-X4 resin (10 The resin was filtered and the filtrate was concentrated to 400 ml. The neutral methanolic solution was warmed to 45 0 C and charged with trisodium phosphate dodecahydrate (129 g, 0.34 moles) and 2chloroethanol (18.2 ml, 0.272 moles). The.reaction was stirred at 45 0 C for 48 hr, when chloroethanol (4.7 ml, 0.07 moles) and sodium methoxide (14.7 g, 0.07 moles) was added. After 71 hr, HPLC indicated the reaction had gone to completion. The insoluble salts (89 g) were removed by filtration and the solution neutralized S15 with hydroxhloric acid (6 N, 7 ml). The solution was concentrated to obtain a brown foam (11) (94 g, 0.12 moles, 92% yield).
IEXAMPLE 11 Amidation of 5-nitroisophthalic acid, monomethyl ester with 3-amino- 1,2-propanediol into: 5-nitro-3-{N-(2,3dihydroxypropyl))carbamoyl benzoic acid (12) The starting material 225 g, 1 mole) was mixed with 3-amino-l,2-propanediol (227.8 g, 2.5 moles) and the heterogeneous mixture was heated to 110-120°C for 1 hr. At this point, the reaction was complete, and the homogeneous mixture was mixed with water (1 L), and concentrated HC1 (170 ml). The mixture was cooled for several days to fully precipitate the product, and the solid was filtered off and washed with cold water ml x Vacuum drying gave a white solid (12, 193 g, 68% yield).
EXAMPLE 12 Reduction of 5-nitro-3-(N-(2,3-dihydroxypropyl)}carbamoyl benzoic acid (12) with hydrogen and palladium-on-carbon into: 5-amino-(hydrochloride)-3-(N-(2,3dihydroxypropyl)}carbamoyl benzoic acid (13) The nitro acid (12, 180 g, 0.634 moles) was mixed with water (1 and concentrated HC1 (60 ml) and 10% palladium-on-carbon (18 g) were added. The suspension was hydrogenated at 2-4 atmospheres until the pressure remained constant, by which time HPLC and TLC indicated reaction completion. The palladium-on- S carbon was removed by filtration and the homogeneous solution was used without product isolation for the 15 following reaction (13, approximate yield 98%).
EXAMPLE 13 Iodination of 5-amino-(hydrochloride)-3-{N- (2,3-dihydroxypropyl)}carbamoyl benzoic acid (13) with iodine monochloride into: 2,4,6-triiodo-3-{N-(2,3-dihydroxypropyl))carbamoyl benzoic acid (14) The title compound (13, ca. 0.62 moles in L water) was further diluted with water to a total volume of 4 L.and heated to 85 0 C. Over 20 minutes, L: iodine monochloride (4.1 molar, 499 ml, 2.05 moles) was added and the temperature maintained at 90°C for 6-8 hr. HPLC indicated reaction completion. The homogeneous mixture was cooled, extracted with 1,2dichloroethane:cyclohexene 500 ml x followed by 1,2-dichloroethane (250 ml x The aqueous layer was then concentrated by distillation to 0.9 L, and cooled for several days to complete the precipitation of the solid. Filtration, washing with cold water (100 ml x 2) and vacuum drying gave the tan product (14, 286 g, 73% yield).
EXAMPLE 14 Acetylat ion of 5-amino-2, 4, 6-triiodo-3- (N-(2,'3-dihydroxypropyl) }carbamoyl benzoic acid (14) with acetic anhydride into: 5-diacetylamino-2, 4, &-triiodo-3-(N- (2,3-diacetoxypropyl)lcarbamoyl benzoic acid The starting material (14, 100 g, 0.158 moles) was mixed with acetic anhydride (300 ml, 3.16 moles) and 70% perchioric acid (0.2 ml), and heated to 80-90 0
C
for 8 hr. The mixture was neutralized with anhydrous sodium acetate (0.25 g) and the acetic anhydride and acetic acid removed by distillation at 70-800C. The oily. residue was azeotroped with butyl acetate (100 ml x then dissolved in ethyl acetate (250 al), and taken directly into chlorination (15, approximate yield' EXAMPLE .*Chlorination of 5-diacetylamino-2 ,4,6triiodo-3-{N-(2,3-diacetoxypropyl))carbamoyl benzoic acid (15) with thionyl chloride into: 5-diacetylamino-2, 4,6-trilodo eeoc. -3-(N-(2,3-diacetoxypropyl) Icarbamoyl benzoyl chloride (16) To the starting m~aterial (15, ca. 0.142 moles) i..in ethyl acetate (225 ml) was added thionyl chloride (57 ml, 0.78 moles) at 65-700C, and the temperature increased afterwards to 75-BOOC for 1 hr. Thionyl chloride and ethyl acetate were vacuum distilled. The residue was azeotroped with butyl acetate (100 ml x 2), and vacuum dried. The brown foam (16, ca. 130 g, estimated yield 95%) was taken directly into the subsequent amidation step.
EXAKPLE 16 Amidation of 5-diacetylamino-2,4,6-triiodo- 2, 3-diacetoxylpropyl) )carbamoyl benzoyl chloride (16) with ammonia into: 2, 4,6-triiodo-3-{N-(2,3-diacetoxypropyl))carbamoyl benzamide (17) The acid chloride (16, ca. 0.135 moles), was dissolved in dry N,N-dimethylacetamide (150 ml). This solution was cooled to 0-50C, anhydrous ammonia (ca. 2U ml) was condensed into the mixture using a dry ice/acetone condenser and the reaction m~ixture was kept sealed at room temperature for 24 hr. The ammonia and DMA were removed by vacuum distillation. 1-pentanol (500 ml) precipitated'a solid which was filtered anc6 washed with 1-pentanol (150 ml x Vacuum drying gave a tan solid (17, 82 g, 80.2t yield).
4 0 0 EXAXPLE 17 Deacetylation of 5-acetylamino-2 ,4,6triiodo-3-(N-( 2,3-diacetoxypropyl) )carbamoyl benzamide (17) into: 5-acetylamino-2,4,6triiodo-3-(N-(2,3-dihydroxypropyl)) carbamoyl benzamide (18) e.:o *The title compound (17, 81.2 g, 0.107 moles) was suspended in water (203 ml) and, then treated with the dropwise addition of 50% w/v sodium hydroxide in water (16.9 ml, 0.322 moles). With stirring, total solution was -obtained. The solution was degassed under vacuum for 30 min at which time 12 M ECl (15 ml, 0.18 moles) was added. After storage at 40C, the resulting precipitated solid was filtered, washed with ice water (3 x 50 ml), ethanol (80 ml), and vacuum dried to the product (18, 54.1 g, 75t yield).
EXAMPLE 18 Alkylation of 5-acetylamino-2,4,6-triiodo-3- (N-(2,3-dihydroxypropyl)}carbamoyl benzamide (18) into: 5-(N-(2,3-dlhydroxypropyl) acetamido}-2,4,6-triiodo-3-(N-(2,3dihydroxypropyl)}carbamoyl benzamide (19) The title compound 39.7 g, 0.059 moles) was dissolved in propylene glycol (16.7 ml), ethanol (120 ml), and 25% w/w sodium methoxide (17.6 ml, 0.077 moles). Chloropropanedici (9.78 g, 0.0885 moles) was added and the mixture was stirred at 25°C for 1 hr.
The reaction was warmed to 33 0 C and stirred for another 19 hr during which time 25% w/w sodium methoxide (3.4 ml, 0.015 moles) was added. The reaction was quenched ]5 with 12 M HC1, distilled under vacuum, reconstituted with H 2 0 (200 ml), and disttilled again to give an aqueous solution that was deionized with Dowex 50 H+ resin (62 g) and Duolite A-340 OHR resin (140 g).
Elution of the resins with H20 and concentration gave a 150 g solution that was treated with Norit Ultra SX charcoal (1.00 g) at 600C for 14 hr. The charcoal was filtered giving an aqueous solution that was stirred for 2 hr with Dowex 50 8H (1.0 g) and Duolite A-340 OH~ (4 The resin Was filtered and the aqueous solution was distilled to 50.3 g of an oil containing the product (19, 32.8 g, 74% yield) in a glycerol/propylene glycol base. This oil was purified as described in the following step.
EXAMPLE 19 Peracetylation, silica column purification, and subsequent deacetylation of: (2,3-dihydroxypropyl)acetamido)-2,4,6triiodo-3-(N-(2,3-dihydroxypropyl)) carbamoyl benzamide (19) The title conpound (19, 16.4 g, 0.022 moles) dissolved in glycerol/propylene glycol oil (total mass, 25.15 g) was diluted with pyridine (1.74 g, 0.022 moles) and acetic anhydride (115 g, 1.12 moles), and then warmed to 60°C for 18 hr. The reaction was distilled under reduced pressure to an oil, dissolved in CHC1 3 (100 ml) and extracted with 0.1 N HC1 (2 x ml) and 15% w/v brine (2 x 50 ml). The CHC1 3 layer was dried over MgS0 4 filtered, and distilled to an oil.
This oil was purified on a 900 g silica column utilizing a solvent gradient which ran from 5% acetic acid, 95% chloroform to 5% acetic acid, 4% methanol, 91% chloroform. Purified fractions were combined, distilled to a foam, and then treated with methanol ml) and 25% w/w sodium methoxide in methanol (0.98 g, 0.0054 moles). After 30 min, the solution was 9* 15 distilled, reconstituted with methanol (20 ml), and then stirred with Dowex 50 H+ resin (1.3 After the pH decreased from 12 to 5, the resin was filtered off, giving a solution that was distilled to a foam, reconstituted with H 2 0 (25 ml), and evaporated to the 20 solid title compound (19, 8.12 g, 49% yield).
EXAMPLE .Deacetylation of 5-diacetylamino-2,4,6triiodo-3-(N-(2,3-diacetoxypropyl)}carbamoylbenzoic acid (15) into: i. 2,4,6-triiodo-3-(N-(2,3-dihydroxypropyl)}carbamoyl benzoic acid The- title compound (15, 720 g, 0.9 moles) was dissolved in 500 ml methanol, and 25% w/w sodium .e 30 methoxide in methanol (345 ml, 1.5 moles) was added.
After 4 hr at 45-500C the reaction was distilled under reduced pressure, acidified with 12 M HC1 (124 ml, moles), and the salts filtered off. The filtrate was distilled under reduced pressure to give an oil which was diluted with n-propanol (680 ml). After crystallizing at 4°C, the resulting solid product was filtered off, washed with n-propanol (2.x 300 ml), and dried in vacuo. Yield was 391 g EXAMPLE 21 Alkylation of 5-acetylamino-2,4,6-triiodo -3-(N-(2,3-dlhydroxypropyl))carbamoy. benzoic acid (20) into: 5-(N-(2,3-dihydroxypropyl acetamido)-2 6-triiodo-3-(N-) 2,3dihydroxypropyl) Icarbamoyl benzoic acid, sodium salt (21) The title compound (20, 100 g, 0.148 moles) was dissolved in 400 ml methanol. Solid Na 3
PO
4 *12 :'i 2 0 (140.6 g, 0.37 moles) was added, followed by chioropropanediol (32.7 g, 0.296 moles) and 25% w/w sodium methoxide in methanol (24.1 g, 0.111 moles), added dropwise. The reaction mixture was warmed to 40 0 C for 10 hr during which more 25% sodium methoxide g, 0.0368 moles) was added in portions. Salts a were filtered off and the methanol filtrate was 6 acidified with 12 M HCl (3.5 rotavaped to a thick oily product (21) and carried directly into the next reaction.
EXA14PLE 22 Acetylation of the sodium salt of dihydroxypropyl)acetamido}-2,4,6-triiodo- 3- 3-dihydroxypropyl) Icarbamoyl benzoic acid121l) into: 5-(N-(2,3-diacetoxypropyl) acetamido)-2, 4, 6-triiodo-3-(N- (2,3diacetoxypropyl))carbamoyl benzoic acid (22) The title compound (21, 114 g, 0.148 moles) oil, was diluted with pyridine (11.7 g, 0.148 moles) and acetic anhydride (605 g, 5.92 moles) and stirred at 65-70* 0 C for 2 hr. The reaction was distilled to an oil, azeotroped with butyl acetate (2 x 100 ml), and partitioned between w.ater (300 ml) and 3:1 toluene:ethyl. acetate (200 ml). The water layer was extracted with 3:1 toluene:ethyl acetate (3 x 100 ml) and acidified with HU (22.5 ml) in the presence of ethyl acetate (300 ml). The acidified H 2 0 layer was separated and extracted twice with ethyl acetate (100 ml). The three latter ethyl acetate extracts were combined, dried over MgSO 4 filtered, and evaporated to a solid product (22, 118 g, 87% yield).
EXAMPLE 23 Chlorination of 5-(N-i 2,3-diacetoxypropyl)acetamido)-2, 4, 6-triiodo-3-(N-( 2, 3-diacetoxypropyl)}carbamoyl benzoic acid (22) into: 5-(N-(2,3-diacetoxypropyl)acetamido)-2,4,6triiodo-3-(N- 3-diacetoxypropyl) 1carbamoyl benzoyl chloride (23) The title compound (22, 113.6 g, 0.124 moles) was dissolved in ethyl acetate (100 ml) at 55 0
C;
a At thionyl chloride (44 g, 0.37 moles) was added dropwise a 41 and the mixture was ref luxed for 2 hr, rotavaped to an oil, and then azeotroped with butyl acetate (2 x 50 ml) to give a foam which was dissolved in chloroform (200 ml) and extracted with 0.2 M. pH 6.7 phosphate buffer (100 ml) The organic layer was d~ried over lMgSO 4 filtered, and evaporated to a solid product (23, 115 g, 98% yield).
EXAMPLE 24 Amidat~ion of 3-diacetoxypropyl) acetamido}-2, 4, 6-triiodo-3-(N- (2,3diacetoxypropyl) Icarbamoyl benzoyl chloride (23) into: 5-{N-(2,3-diacetoxypropyl )acetamido)-2 6-triiodo-3-(N- (2,3diacetoxypropyl) )carbamoyl benzamide (24) The title compound (23, 105 g, 0.111 moles) was dissolved in acetonitrile (400 ml) to which anhydrous ammonia was added by utilizing a dry ice condenser at 25 0 C. After 3 hr Of NH 3 ref lux, the reaction was complete. Salts were filtered off, and evaporation yielded a solid product (24, 98.8 g, 96% yield).
EXAMPLE 2 Deacetylation of 5-(N-(2,3-diacetoxypropyl) acetamido}-2, 4, 6-triiodo-3-(N-( 2,3diacetoxypropyl) )carbamoyl benzamide (24) into: 2,3-dihydroxypropyl)acetamido) -2,4,6-triiodo-3-(N-(2,3-dihydroxypropyl)) carbamoyl benzamide (19) The title compound (24, 98.7 g, 0.105 moles) was dissolved in methanol (250 mi) to which 25% w/w sodium methoxide in methanol (2.30 g, 0.0106 moles) was t 9VO added at 25*C. After 15 min, the solution was distilled under vacuum to an oil, reconstituted with methanol (200 ml) and then stirred with Dowex 50 H resin (6.0 g) until the pH decreased from 12 to 6. The resin was filtered off to produce a solution that was distilled to a foam, reconstituted with water (320 ml) and Norit SX charcoal (3.0 refluxed for 7 hr, filtered, deionized by stirring with Dowex 50 H resin (3 g) and Dowex XUS-40123 0H- resin (12 filtered, and evaporated to the solid product (19, 79.2 g, 96% yield).
EXAMPLE 26 Methoxyacetylation of 5-amino-2,418-triiodo -3-CN-(1,3,4-trihydroxy-threo-but-2-yl))cC carbamoyl benzamide with iethoxyacetyl chloride into: .5-methoxyacetylamino-2,4,6tr iiodo-3-(N- 4-trihydroxy-Lhreobut-2-yl))carbamoyl benzamide The title compound 100 g, 0.15 moles) was suspended in N,N-dimethylacetamide (250 ml) at 250C to which was added methoxyacetyl chloride (68 ml, 0.75 moles) over 30 min. The reaction mixture was stirred at 35*C for 5 hr, when HPLC indicated that the reaction was complete. The reaction mixture was quenched with sodium methoxide (97 g, 0.45 moles) and the mixture was stirred at 40 0 C for 2 hr. The solution was neutralized with Dowex 50W-X4 resin, filtered and diluted with n-butanol (700 ml). A white precipitate formed immediately and was filtered to obtain an off-white solid (25, 80.6 g, 0.11 moles, 73% yield).
EXAMPLE 27 Alkylation of Ioxithalamic Acid (26) to: 2,3-dihydrOxypropyl)acetamido)-2,4,6-triiodo- 2-hydroxyethyll))carbamoyl sodium benzoate (27) Ioxithalamic acid (26, 966 g, 1.5 moles) was dissolved in 1 N sodium hydroxide (1.5 L) at room is. 1 temperature, warmed to 75 0 C, and 3-chloro-l,2--propanediol (223.8 g, 2.03 moles) and 5 N sodium hydroxide (approximately 0.4 L) were added simultaneously over 1.25 hours. The reaction was heated at 80-90 0 C for a further 2.5 hours, at which point HPLC showed completion of the reaction (ca. 90% conversion to product).
The reaction mixture-was neutralized with concentrated hydrochloric acid (ca. 3 ml) and evaporated. About half of the foamy residue was taken up in water (0.4 On cooling, a uhite, crystalline solid precipitated, which was filtered and washed with ice cold water. Drying gave the crystalline product (27, 249 *av 30 EXAMPLE 28 Acetylation of (2 ,3-dihydroxypropyl) acetamido)-2, 4 ,6-triiodo-3-(N- (2-hydroxyethyl)) carbamoyl-sodium benzoate (27) to., 5-(N-(2,3-diacetoxypropyl)acetamido)-2,4 ,6-triiodo- 3-{N-(2-acetoxyethyl))carbamoyl-benzoic acid (28) The title compound 50 g, 0.067 moles) was added to stirred acetic anhydride (102 ml, 1.080 moles, 16.0 eq.) at 25 0 C Pyridine (5.4 ml, 0.067 moles, eq.) was added and the temperature was raised to for 1 hour when TLC indicated the reaction had gone to completion. The homogeneous reaction mixture was evaporated in vacuo to a thick oil, dissolved in butyl acetate (50 ml) and repeatedly evaporated. The oil was dissolved in H 2 0 (260 ml) and extracted with toluene:ethyl acetate 4 x 100 al). The aqueous layer was acidified with 12 N hydrochloric acid (11 ml) and extracted with ethyl acetate (3 x 50 ml). The organic layer wa's dried over magnesium sulfate, evaporated to a foam (28) and taken directly to the next step (55 g, 0.065 moles, 97% yield).
0:06~ 0006 15 EXAMPLE 29 eChlorination of 5-{N-(2,3-diacetoxypropyl) Racetamido)-2,4,6-triiodo-3-(N-(2-acetoxyethyl)}carbamoyl-benzoic acid (28) to: 4,te, 5-(N-(2,3-diacetoxypropyl)acetamido)-2,4,6-triiodo-3- 2-acetoxvethyl) }carbamoyl-benzoy1 chloride (29) The title compound (28, 55 g, 0.065 moles) was dissolved in l,2-dichloroethane (170 ml]) and heated to 85 0 C. Thionyl chloride (9.8 ml, 0.134 moles, 2.0 eq.
was added and TLC indicated the reaction had reached completion after 3 hodrs. The reaction mixture was evaporated in vacuo to an oil, redissolved in butyl acetate (50 ml) and-repeatedly evaporated. The product was isolated'as a yellow foam 51.9 g, 0.060 moles, 92% y'eld).
EXAMPLE Amidation of 5-(N-(2,3-diacetoxypropyl) acetamido)-2, 4, 6-triiodo-3-{N- (2-acetoxyethyl)) .carbamoyl-benzoyl chloride to: 5-{N-(2,3-diacetoxypropyl)acetamido)-2,4,6-triiodo- (2-acetoxyethyl) )carbamoyl-benzamide The title compound (29, 51.9 g, 0.060 moles) was dissolved in acetonitrile (200 ml) and anhydrous ammonia (excess) was added at 10 0 C. After 4 hours, TLC indicated the reaction was complete. The reaction mixture was filtered to remove ammonium chloride salts and the solvent was removed to give a yellow oil 47 g, 0.056 moles, 93% yield).
EXAMPLE 31 Deacetylation of 5-{N-(2,3-diacetoxypropyl) acetamido}-2,4c6-triiodo-3-{N-u9-acetoxyethyl)}carbamoyl-benzamide (30) to: 5-(N-(2,3-dihydroxypropylacetamido))-2,4,6-Ltriiodo- 3-(N-(2-hydroxyethyl) carbamoyl-benzamide (31 The title compound (30, 47 g, 0.056 moles) was 15. dissolved in methanol (240 ml) and 25% sodium methoxide I (3.9 g, 0.3 eq.) was added to raise the pH to ca. 12.
The solution wa stirred at 25°C for 1 hour when HPLC indicated the deacetylation was complete. The reaction mixture was neutralized with 1 N HC1 (10 ml) and *20 solvent removal gave an off-white foam (31, 39 g, 0.054 moles, 97% yield, 98% pure), which was recrystallized from hot methanol (5 g in 15 ml, with seeding).
EXAMPLE 32 25 Amidation of 5-amino-2,4,6-triiodoisophthaloyl chloride (32) into: 5-amino-2,4,6-triiodo-3-chlorocarbonyl-benzamide (33) The starting material (32, 300 g. 0.503 moles) was dissolved in tetrahydrofuran (900 ml) and the homogeneous solution cooled in ice to 5-10°C.
Concentrated ammonium hydroxide (92.3 ml, 1.38 moles) was added over 10 minutes; the temperature rose to 0
C.
The reaction mixture was stirred at room temperature for a total of 90 hours, with further additions of ammonium hydroxide (total 25.2 ml, 0.38 moles), then it was cooled and the insoluble salts removed by filtration. The filtrate was washed with saturated NaCi (200 ml x 2).
The tetrahydrofuran, was evaporated to give a viscous oil. El,'l acetate (800 ml) precipitated a tan solid which, was Altered, washed with ethyl acetate (100 ml x 2) and dried to give (33, 193 g, 66.5% yield).
EXAMPLE 33 Dimerization of 5-amino-2,4,6-triiodo-3chlorocarbonyl-benzamide (33) infto: Malonic Acid-bis-( carbamoyl)-2,4,6-triidodanilide) (34) The title compound (33, 20.0 g, 34.7 mM) was 090415 dissolved in dry tetrahydrofuran (100 ml), heated to 2 450C, and malonyl dichloride (2.53 ml, 26 mM) was added over 3 minutes to give a heterogeneous mixture. Dry ~THF (100 al) was added, and the suspension stirred- for 1 hour when TLC shbwed the reaction to be complete.
9 The mixture was diluted with butyl aceta te (150 ml), and the solid was filtered, washed with butyl: acetate ml 2) and dried in. vacuo to give the product (34, 13.18 g, 62% yield).
EXAMPLE 34 Amidation of Malonic Acid-bis-(h3-chlorocarbonylsob 5-carbamoyl)-2,4,6-tri.odoanilide) (34) into: Malonic Acid-bis-f {3-N-(l,3,4-trihydroxy-threo-but-2yl-carbamoyl-5-carbamoyl)-2,4,6-triiodoanilide] The title compound (34, 8.0 g, 6.56 mM) was dissolved in dry N,N-dimethyl-acetamide (10 ml), triethylamine (1.83 ml, 13.12 mM.) was added and the solution was cooled to 200C. Trans-5-amino-2,2dime thy1l'6-hydroxy-l, 3-dioxepan (2.64g, 16.4 mM.) was added over 3 minutes, and the homogeneous mixture was stirred at room temperature for 6 hours, when TLC indicated the reaction was complete. The solvent was evaporated, water (50 ml) was added, and the mixture was heated at 75 0 C for 15 minutes to cleave the acetonides. The product was obtained by evaporation and precipitation with isopropanol (100 ml). The solid was filtered, washed with isopropanol (20 ml x 2) and dried to give 8.6 g (35, 94% yield).
EXAMPLE Amidation of 5-i-methylamino-2,4,6-tr i iodoisophthaloyl-chloride (36) to: 5-N-methylamino-2,4,6-triiodo-3chlorocarbonyl-benzamide (37) The starting material (36, 305 g, 0.5 moles) was dissolved in tetrahydrofuran (1 L) and cooled to 15 10 0 C. Concentrated ammonium hydroxide (100 ml, moles) was added over 5 minutes; the temperature rose i. to ca. 25 0
C.
The reaction mixture was stirred at room temperature for 65 hours, with additional portions of 20 concentrated NH 4 0H added at 20 hours (3.5 ml) and 44 hours (3.5 ml).
Upon cooling, the insoluble salts and bisamide were filtered and the THF filtrate washed with saturated sodium chloride solution (100 ml x 2).
a 25 The THF was evaporated and the product precipated from the thick oil by ethyl acetate (500 ml). Filtration, washing with ethyl acetate and drying gave (37, 132.1 g, 45% yield).
"ar 30 EXAMPLE 36 Dimerization of 5-N-methylamino-2,4,6-triiodo- 3-chlorocarbonyl-benzamide (37) into: Malonic carbamoyl)-2,4,6-triiodo-N-methyl anilide) (38) The title compound (37, 25 g, 42.3 mM) was dissolved in dry tetrahydrofuran (100 ml) and the homogeneous solution was heated to 50°C. Malonyl se*~ a..
4 dichloride (3.05 ml, 31.3 mM) was added over 2 minutes, followed by additional tetrahydrofuran (50 ml) and the suspension wasj heated for one hour, when TLC showed the reaction was complete.
Uipon dilution with butyl acetate (50 ml), the product was filtered, washed with butyl acetate (25 ml x 2) and dried to give an off-white solid (38, 15.24 g, 58% yield).
EXAMPLE 37 Transformation of Malonic Acid-bis-( (3-chlorocarbonyl- S-carbamoyl)-2,4,6-triiodo-N-methyl anilide) (38) into: Malonic Acid-bis-( (3-N-(1,3,4-trihydroxy-threobut-2-yl-carbamoyl 5-carbamoyl)-2, 4, 6-triiodo- 15 N-methyl anilide] (39) The starting material (38, 10 g, 8 mM) was dissolved in dry N,N-dimethyl-acetaaide (15 m.1) and triethylamine (2.23 ml, 16 mM). Trans-5-amino-2,2dime thyll-6-liydroxy-1, 3-dioxepan (aminodioxepan) (3.22 g, 20 mM) was added over 5 minutes, and the homogeneous mixture was stirred for 8 hours, when TLC showed the reaction to be complete.
The DM4A was removed by vacuum distillation and the isopropylidenes were cleaved with aqueous hydrochloric acid at 500C. The water was removed on the rotary evaporator and isopropanol, added to precipitate the product. Filtration, washing with isopropanol ml x 3) and drying gave the dimer (39, 9.86 g, 87% yield).
EXAMPLE 38 )amino-2 6-triiodo-3chlorocarbonyl-benzamide (36) into: 5-{N-(methyl)-2-acetoxyacetamido)-2,4 ,6triiodo-3-chlorocarbonyl-benzamide (401 The starting material (36, 25 g, 42.3 mM was dissolved i"n dry N,N-dimethyl--acetamide (50 ml) at room 4e
C
eCe temperature. 2-Acetoxyacetyl chloride (6.83 ml, 63.5 mM) was added, and after stirring overnight, TLC indicated the reaction was complete.
The product was precipitated by the addition of ice-cold water (200 ml) and filtered. After washing with water the solid was dissolved in tetrahydrofuran (200 ml), and the solution extracted with saturated NaCl:saturated NaHCO 3 250 ml), followed by saturated NaC1 (100 ml). The organic layer was dried (MgSO 4 and the solvent removed to give a foam 22.1 g, 77.2% yield).
EXAMPLE 39 Amidation and Deprotection of 15 2-acetoxyacetamido}-2,4,6-triiodo-3e9 chlorocarbonyl-benzamide (5a) into: 5-(N-(methyl)-2-hydroxyacetamido)-2,4,6-triiodo- 3-(N-(1,3,4-trihydroxy-threo-but-2-yl)} a; carbamoyl-benzamide (51) The title compound (50. 7.0 g, 10.35 mM) was dissolved in a mixture of tetrahydrofuran (40 ml) and triethylamine (1.44 ml, 10.35 mM) and cooled to Solid aminodioxepan (2.0 g, 12.41 mM) was added, the cooling was removed and the reaction was allowed to stir at 25 0 C. By 18 hours, TLC indicated reaction completion. The reaction mixture was diluted with tetrahydrofusan (40 ml) and saturated NaCl:saturated NaHCO3 50 ml) and the layers were separated. .The organic Layer was washed with saturated NaCL (40 ml x dried (MgSO 4 and the solvent evaporated to give a foam (6.9 g, 821 yield).
The foam was dissolved in methanol (50 ml) and 4.6 f6rmal NaOMe solution (0.5 ml) added. The solution was stripped at 50 0 C to yield an oil which was subsequently mixed with water (50 ml) and Dowex 50 H resin (10 Heating at 60 0 C for 30 minutes eventually gave a homogeneous solution, and BPLC O8O Gh/AD 35 indicated that ester and isopropylidene cleavage was complete.
The resin was filtered, and the solution cycled through sequential Duolite A 340 OHY-/Dowex 50 H columns until deionization was complete. The compound was eluted from the columns with water and subsequently treated with Norit Ultra S-X carbon (0.4 After 1 hour at 70° C, the carbon was filtered and the water evaporated to yield a white foam (51, 3.8 g, 50% yield from EXAMPLE Acetoxyacetylation of 5-amino-2,4,6-triiodo- 3-chlorocarbonyl benzamide (33) into: 5-acetoxyacetylamino-2,4,6-triiodo-3chlorocarbonyl benzamide (42) The starting material (33, 200 g, 0.347 moles) in 1200 ml dioxane was heated to 60 0 C. Acetoxyacetyl 0 chloride (142 g, 1.041 moles) was added dropwise over minutes at which time the reaction was heated to 90 0 C and o* held there for 6.5 hours. After cooling to 15 0 C the solid product (42) was filtered, washed with 4 x 100 ml dioxane and vacuum dried to a weight of 200.5 g (yield EXAMPLE 41 Amidation of 5-acetoxyacetylamino-2,4,6- .triiodo-3-chlorocarbonyl benzamide (42) into: 5-acetoxyacetvlamino-2,4,6-triiodo-3-{N-2,3dihydroxypropyl) -carbamoyl benzaride 43) The starting material (42, 118 g, 0.174 moles) was added to, a flask containing N,N-dimethyl acetamide (180 ml), 3-amino-1,2-propanediol (24.2 g, 0.266 moles) and triethylamine (18.6 g, 0.177 moles). The reaction was held at 25°C for 4 hours and was then diluted by the dropwise addition of n-pentanol (1080 ml) during vigorous mechanical stirring. The resulting precipitate (43) was filtered, washed with 4 x 100 ml n-pentanol, and vacuum dried to a weight of 124.9 g (crude yield 98%).
000611/ABDX 36 EXAMPLE 42 Deacetylation of 5-acetoxyacetylamino-2,4,6triiodo-3-{N-(2,3-dihydroxypropyl)}-carbamoylbenzamide (43) into: 5-hydroxyacetvlamino-2,4,6-triiodo-3-{N-(2,3dihydroxypropl) }-carbamovl benzamide (44) The starting material (43, 124.8 g, 0.170 moles) was dissolved in methanol (1.5L) and water (0.5 L) and then treated with Dowex H+ and Biorex 5 -OH ion exchange resins. The resins were removed with a sieve after hours of stirring and the resulting mixture was distilled under reduced pressure to a solid residue. Methanol (400 ml) and 25% w/w sodium methoxide in methanol (36.9 g, 0.17 moles) were added to the residue to produce a solution which was filtered, distilled under pressure to remove methyl acetate, diluted with methanol, neutralized with concentrated HC1 and then distilled under reduced pressure to a solid consisting of 9.9 g NaC1 and 94.0 g of the S product The yield was EXAMPLE 43 Protection of 5-hydroxyacetylamino-2,4,6-triiodo- 3-{N-(2,3-dihydroxypropyl)}-carbamoyl benzamide (44) 9949 ~with 3,4-dihydro-2H-pyran into: 5-(2-tetrahvdropyranyloxv)acetylamino-2,4,6-triiodo- 3-{N-(2,3-tetrahvdropvranloxy)propl} 'carbamovl benzamide The starting material 3.44 g, 5 mMoles) was mixed with dioxane;(15 ml) and methanesulfonic acid (29.6 mg 0.31mMoles). 3,4-Dihydro-2H-pyran (3.36 g, 40 mMole) was added and the mixture was stirred at 25 0 C for 4 days.
The reaction was filtered, basified with triethylamine (62 mg, 0.62 mMole), distilled under reduced pressure to an oil, reconstituted with methanol, and distilled under reduced pressure to a product residue (45) which .as carried directly into alkylation.
008 6/ABO 4 -37- EXAMPLE 44 Alkylation and Deprotection.
of 5-(2-tetrahydropyranyloxy)acetylamino-2, 4,6triiodo-3-{N-(2, 3-tetrahydropyranyloxy)propyl)carbamoyl benzamide (A5) into: 5-{N-(2-hvdroxyethvl)hvdroxyacetamido 4 6triiodo-3-fN-2,.3-dihvdroxvnropvl) carbamovlbenzamide (46) The starting material was (45. 5.0 mMole), a semisolie. r esidue from the previous step, was mixed with methan,.A (14t ml), trisodium phosphate dodecahydrate (4.75 g, 12.5 W1oles) and chioroethanol (805 mg, 10 mMoles).
The resulting suspension was stirred at 40-45 0 C for 31 hours, filtered and diluted with 0.5 ml concentrated HCl.
The acidified filtrate was distilled under redtuced pressure to an oil and reconstituted with 0.01 N HCl ml) and methanol (20 ml). After repeating this twice *more, the acidic solution was finally distilled under reduced pressure to solid product weighing 3.50 g, yield EXAMPLE Alkylation of 3, 5-diacetylamino-2, 4,6triiodobenzoit- acid (diatrizoic acid, 47) into: Sodium 3.5-(NNN-(2,3-dihdroxpropvl)diacetamido.- 2.4. 6-triiodobenzoate (48) To a suspension of the starting material (47, 50 g, 0.079 moles) in methanol (300 ml) was added trisodium phosphate dodecahydrate (149 g, 0.393 moles) and 3-chloro-J1,2-propanediol (35 g, 0.314 moles) and the reaction was heated at 40 0 C for 24 hours. Insoluble salts were removed by vacuum filtration, the filtrate was neutralised with HG]. and evaporated to a white foam (A-8, ca. 59 g, yield 94% including 10% ester byproduct). The foam was taken directly into acetylation.
0f086h/ADD -38 EXAMPLE 46 Acetylation of Sodium (2,3-dihydyproxypropyl)diacetamido}-2,4,6triiodobenzoate (48) into: 3.5-{N,N'-(2,3-diacetoxypropyl)diacetamido}- 2,4,6-triiodobenzoic acid (49) The starting material (48, 59 g, 0.075 moles) was mixed with acetic anhydride (150 ml, 1.58 moles) and pyridine (6 ml, 0.075 moles) and heated to 85 0 C for 1 hour. The acetic anhydride, acetic acid, and pyridine were removed by distillation at 70-80 0 C, and the yellow foam was azeotroped with butyl acetate (50 ml x x2).
The product (sodium salt of 49) was dissolved in water (300 ml) and extracted with a 2:1 mixture of toluene *Vs.
and ethyl acetate (150 ml x 3) to remove the ester byproduct from the previous alkylation step. The aqueous S* solution was acidified with concentrated HC1 to pH 2.5 and the white precipitate was extracted with ethyl acetate ml x The combined organic extracts were dried over magnesium sulfate and the solvent removed to give a yellow oil (49, ca. 58 g, 83% yield overall from 47). The product was taken directly into chlorination.
EXAMPLE 47 Chlorination of (2,3-diacetoxypropyl)diacetamido}-2,4,6triiodobenzoic acid (49) into: 3,5-{NN'-(2,3-diacetoxypropyl)diacetamido}-- 2,4,6-triiodobenzoyl chloride To the starting material (49, ca. 0.062 moles) in ethyl acetate (125 ml) was added thionyl chloride (23 ml, 0.32 moles) at 65.70 0 C, and the temperature increased to 75-800 for 1 hour. TLC indicated that the reaction was complete and thionyl chloride and ethyl acetate were removed under vacuum. The residue was azeotroped with butyl acetate (150 ml x 2) and the resultant solid dried.
OO00U1VADD C -39 The tan foam (50, ca. 56 g, yield 95% was taken directly into the subsequent arnidation step.
EXAMPLE 48 Amidation of (2,3-diacetoxypropyl)diacetamido}-2,4, 6triiodobenzoyl chloride (50) into: 3,5-fNN*2,3-diacetoxvprovl)diacetamiio)- 2.4. 6-triiodo-benzamide (5~1) To the starting material (50, ca. 0.059 moles) in acetonitrile (200 ml) was added anhydrous ammonia (excess) at 10 0 C, and the temperature was increased to 25 0 C for hours. The reaction was complete by TLC and the amnmonium chloride was removed by filtration. The filtrate was evaporated to a yellow foam (51, 53 g. estimated yield The foam was taken directly to deacetylation.
EXAMPLE 49 Deacetylation of 3,5-{N,N4- 3-diacetoxypropyl)diacetamido)- 2,,6-tiiodbenzmide(51].) into: 3,5-CNN'--(2.3-dihvdroxvp-roovl)diacetamido}- 2.4. 6-triiodo--benzamide (52j) A solution of the starting material (51, ca 0.057 moles) in methanol (250 ml) was mixed with sodium S methoxide (4.6 molal, 5.0 g, 0.023 moles) and was stirred at room temperatur6 for 30 minutes. HPLC showed that the deacetylation was complete and the reaction mixture was neutralized with concentrated HCl. The insoluble sodium chloride~was removed by filtration and the filtrate was CObS evaporated to a yellow foam (52, 43 g, yield 97%, purity 98% by HPLC).
EXAMPLE Injection solutions containing 5-(N-(2,3-.dihydroxypropyl)acetamido -2,4,6 -triiodo-3- 2,3-dihydroxypropyl) 1carbamoyl benzamide (19) Iodine Content of Injection Composition of 100 ml Solution in mg/mi Aliquots of Solution 300 350 400 Compound 58.87 68.68 78.49 Disodium, calcium salt of ethylenediaminetetraacetic acid (mg) 10 10 Tris-(hytiroxymethyl )aminomethane (n)121 121 121 0:00 06415 Water for injection to volume (ml) 100 100 100 Osmolality (mOsm/kg) 399 473 510 *6 *6Viscosity 370C (centipoise) 4.1 6.6 10.6 Procedure: The sodium-calcium salt of ethylenediaminetetraacetic acid, tris-(hydroxymethyl)aminomethane, and the contrast media were dissolved in water for 6 injection and adjusted to pH 7.0 by the addition of 1 N hydrochloric acid. Solutions were QS'd to 100 al with water for injection, filtered through a 0.22 micron membrane into glass vials, capped, and autoclaved for min at l21*C.
41 EXAMPLE 51 Injections solutions containing hydroxyethyl)acetamido}-2,4,6-triiodo-3-(N-(l,3,4trihydroxy-threo-but-2-yl))carbamoyl benzamide (11) Iodine Content of Injection Composition of 100 ml Solution in mg/ml Aliquots of Solution 300 350 400 Compound 58.87 68.68 78.49 Disodium, calcium salt of ethylenediaminetetraacetic acid (mg) 56 56 56 Trisodium citrate (mg) 77 77 77 Water for injection to volume (ml) 100 100 100 15 Osmolality (mOsm/kg) 301 337 370 4I 000 Viscosity at 370C (centipoise) 4.2 6.6 13.1 Procedure: The calcium-disodium salt of ethylenediaminetetraacetic acid, trisodium citrate, and the contrast media were dissolved in water for injection and adjusted to pH 5.0 to 6.0 with sodium carbonate and carbon dioxide. Solutions were QS'd to 100 ml with water for injection, filtered through a 0.22 micron membrane into glass vials, capped and autoclaved for 20 minutes at 121 0
C.
It is evident from the above results, that novel non-ionic contrast media are provided having substantially superior properties to compounds presently available. Because of the improvement in the physical characteristics, particularly as to osmolality and viscosity, a broad range of body regions may be diagnosed while providing for easy administration and lower pain. Despite the large number of compounds which have been synthesized and tested, the subject compounds are found to be superior to previously disclosed compounds. By providing for three different nitrogens in the molecule, only two of which are substituted, the novel properties are achieved. In addition, synthetic routes are provided which are efficient and provide for high yields, while allowing for the use of readily available materials.
All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
o *g*q

Claims (12)

1. A non-ionic contrast medium of the formula: R 3 CON- R4 CONR 1 R 2 0OeS Su *qI@9 *eq 9 S. .9 0S S. 6 0*. 000 0Si having at least two oxy groups; and wherein: R 1 is hydrogen, lower alkyl or hydroxy-substituted lower alkyl, wherein alkyl is of from 1 to 6 carbon atoms; R 2 is hydroxyalkyl of from 2 to 6 carbon atoms having from 1 to n-1 hydroxyl groups, wherein n is the number of carbon atoms; R 3 is lower alkyl, hydroxy-substituted lower alkyl or lower alkoxy-substituted lower alkyl and of from 1 to 6 carbon atoms, or two R 3 groups may be taken together to form a.bridge of from 0 to 2 carbon atoms; i.e. R 3 stands for CONH 2 I I -(CH2) -2-CON CONR 1 R 2 R4 i -44 and R4 is hydrogen or alkyl of from 1 to 6 carbon atoms having from 0 to n-i hydroxyl groups, wherein n is the number of carbon atoms, with the proviso that said compound is not S-(-)-3-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[2-hydroxy-1-oxopropyl)amino]- 2,4,6-triiodoisophthalamic acid amide.
2. A non-ionic monomeric contrast medium according to Claim 1, wherein R, is of 4 carbon atoms and three hydroxyl groups, R, is other than taken together to form a bridge and R4 is of from two to three carbon atoms and has at least one hydroxyl group.
3. A non-ionic contrast monomeric medium according to Claim 1, wherein R, is of 3 carbon atoms and 2 hydroxyl groups, R, is other than taken together to form a bridge, and R4 is of 3 carbon atoms and 2 hydroxyl groups.
4. A non-ionic contrast medium according to Claim 3, wherein R, and R4 are the same.
5- {N-(2-hydroxyethyl)acetamido)}-2,4,6-triiodo-3- {N-(1,3,4-trihydroxy-threo- but-2-yl)} carbamoyl benzamide.
6. 5- -dihy droxypropyl)acetamido} -2,4,6-triiodo-3- {N-(2,3,dihydroxy- propyl)) carbamoyl benzainide.
7. 5- {N-(2,3-dihydroxypropyl)acetamido} -2,4,6-triioo-3- {N-(2-hydroxyethyl)}- :i carbamoyl benzamide. V U O.It3 l/ U
8. 5-(N-(methyl)-2--hydroxyacetamido)-2,4, 6- triido-3-{N-(1,3,4- trihydroxty-threo-bub--2-yl)}carbamoyl- benzamide.
9. Malonic Acid-bis-1i3-{N(1,3,4-trihydroxy)- threo-but-2-yl) carbamoyl-5--carbamoyl]-2,4, anilide. 5-{N-(2-hydroxyethyl)hydroxyacetamido- 2,4, 6-triiodo-3-{N-(2,3--dihydroxypropyl)}carbamoyl- Sbenzamide (46). 3,5-{N,N'-(2,3-diacetoxypropyl)- diacetamido)-2,4,6-triiodobenzcic acid (49).
12. A radiologic formulation comprising a non-ionic contrast medium according to Claim 1 in a 0.4 physiologically acceptable carrier. 'U13. A radiologic formulation comprising a non-ionic contrast medium according to Claim 5 in a physiologically acceptable carrier.
14. A radiologic formulation comprising a non-ionic contrast medium according to Claim 6 in a physiologically acceptable carrier. -46- In a method for taking a non-invasive determination of a physiologic state using irradiation and a non-ionic contrast medium: the improvement which comprises employing a non-ionic contrast medium according to Claim 1.
16. A non-ionic contrast medium as claimed in claim 1, substantially as hereinbefore described. DATED this 17th day of August 1993. SCHERING AKTIENGESELLSCHAFT By their Patent Attorneys DAVIES COLLISON CAVE C o e *o *o *C CC
AU58694/90A 1989-07-05 1990-07-04 Novel carboxamide non-ionic contrast media Expired AU643447B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37571489A 1989-07-05 1989-07-05
US375714 1989-07-05
US43152789A 1989-11-03 1989-11-03
US431527 1995-05-01

Publications (2)

Publication Number Publication Date
AU5869490A AU5869490A (en) 1991-01-10
AU643447B2 true AU643447B2 (en) 1993-11-18

Family

ID=27007168

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58694/90A Expired AU643447B2 (en) 1989-07-05 1990-07-04 Novel carboxamide non-ionic contrast media

Country Status (16)

Country Link
EP (1) EP0406992B1 (en)
JP (1) JP3249112B2 (en)
AT (1) ATE119783T1 (en)
AU (1) AU643447B2 (en)
CA (1) CA2020489C (en)
CS (1) CS277109B6 (en)
DE (1) DE59008695D1 (en)
DK (1) DK0406992T3 (en)
ES (1) ES2069677T3 (en)
GR (1) GR3015580T3 (en)
HU (1) HU219585B (en)
IE (1) IE65719B1 (en)
IL (1) IL94718A (en)
NO (1) NO179247C (en)
PT (1) PT94595B (en)
RU (1) RU2060246C1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4109169A1 (en) * 1991-03-20 1992-09-24 Koehler Chemie Dr Franz WATER-SOLUBLE NON-IONIC X-RAY CONTRASTING AGENTS AND AGENTS AND METHOD FOR THE PRODUCTION THEREOF
DE4341472A1 (en) * 1993-12-02 1995-06-08 Schering Ag A method for increasing the stability of liposome suspensions containing hydrophilic drugs
GB9618056D0 (en) * 1996-08-29 1996-10-09 Nycomed Imaging As Process
DE19731591C2 (en) * 1997-07-17 1999-09-16 Schering Ag Pharmaceutical compositions containing triiodoaromatics containing perfluoroalkyl groups and their use in tumor therapy and interventional radiology
ITMI20010773A1 (en) * 2001-04-11 2002-10-11 Chemi Spa PROCESS FOR THE PRODUCTION OF HIGH PURITY IOEXOLO
KR20100033405A (en) * 2007-07-12 2010-03-29 지이 헬스케어 에이에스 Contrast agents
EP2240432B1 (en) 2008-01-14 2012-07-04 Mallinckrodt LLC Process for the preparation of iosimenol
EP2093206A1 (en) * 2008-02-20 2009-08-26 BRACCO IMAGING S.p.A. Process for the iodination of aromatic compounds
EP2230227A1 (en) * 2009-03-20 2010-09-22 Bracco Imaging S.p.A Process for the preparation of triiodinated carboxylic aromatic derivatives
BR112012001103B1 (en) 2009-07-07 2021-05-11 Bracco Imaging Spa process for preparing an iodinating agent
AU2013323982B2 (en) 2012-09-27 2017-11-23 Ge Healthcare As Preparation of Ioforminol, an X-ray contrast agent
JP7090645B2 (en) * 2017-05-01 2022-06-24 大塚製薬株式会社 Manufacturing method of iocimenol

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1538076A (en) * 1974-11-15 1979-01-10 Addressograph Multigraph Apparatus for electrostatic reprography
US4273654A (en) * 1979-06-27 1981-06-16 Pielkenrood-Vinitex B.V. Separation device
AU616205B2 (en) * 1988-07-20 1991-10-24 Novo Nordisk A/S Human insulin analogs and preparations containing them

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021481A (en) * 1969-06-27 1977-05-03 Nyegaard & Co. A/S Amido derivatives of 2,4,6-triiodobenzoic acids containing at least one N-hydroxyalkyl and at least two hydroxyl groups
CH608189A5 (en) * 1974-12-13 1978-12-29 Savac Ag
FI760068A (en) * 1975-02-03 1976-08-04 Schering Ag
FR2435253A1 (en) * 1978-07-04 1980-04-04 Nyegaard & Co As PROCESS FOR THE PREPARATION OF A BUFFERED SOLUTION OF A CONTRAST SUBSTANCE FOR X-RAYS, AND PRODUCTS OBTAINED BY THIS PROCESS
DE2909439A1 (en) * 1979-03-08 1980-09-18 Schering Ag NEW NON-ionic x-ray contrast agents
DE3001292A1 (en) * 1980-01-11 1981-07-16 Schering Ag Berlin Und Bergkamen, 1000 Berlin NON-ionic 5-C SUBSTITUTED 2,4,6-TRIJOD ISOPHTHALIC ACID DERIVATIVES
DE3150916A1 (en) * 1981-12-18 1983-06-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen N-HYDROXYAETHYLATED 2,4,6-TRIJODAMINOISIOPHTHALIC ACID-BISTRIHYDROXYBUTYLAMIDES, THEIR PRODUCTION AND THEIR CONTAINING X-RAY CONTRASTING AGENTS "
DE3731542A1 (en) * 1987-09-17 1989-03-30 Schering Ag NEW DICARBONIC ACID-BIS (3,5-DICARBAMOYL-2,4,6-TRIIOD-ANILIDE), METHOD FOR THE PRODUCTION THEREOF AND THESE CONTAINING X-RAY AGENTS
DE3739098A1 (en) * 1987-11-16 1989-05-24 Schering Ag NEW SUBSTITUTED DICARBONIC ACID-BIS (3,5-DICARBAMOYL-2,4,6-TRIYOD ANILIDE), METHOD FOR THE PRODUCTION THEREOF AND THEIR CONTAINING X-RAY CONTRASTING AGENTS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1538076A (en) * 1974-11-15 1979-01-10 Addressograph Multigraph Apparatus for electrostatic reprography
US4273654A (en) * 1979-06-27 1981-06-16 Pielkenrood-Vinitex B.V. Separation device
AU616205B2 (en) * 1988-07-20 1991-10-24 Novo Nordisk A/S Human insulin analogs and preparations containing them

Also Published As

Publication number Publication date
AU5869490A (en) 1991-01-10
HUT57708A (en) 1991-12-30
IE902340A1 (en) 1991-01-16
JP3249112B2 (en) 2002-01-21
IL94718A (en) 1994-10-21
NO179247C (en) 1996-09-04
PT94595A (en) 1991-03-20
CS335390A3 (en) 1992-01-15
EP0406992A3 (en) 1991-09-18
NO902986D0 (en) 1990-07-04
DK0406992T3 (en) 1995-07-24
IL94718A0 (en) 1991-04-15
EP0406992B1 (en) 1995-03-15
PT94595B (en) 1997-02-28
EP0406992A2 (en) 1991-01-09
HU219585B (en) 2001-05-28
IE65719B1 (en) 1995-11-15
CA2020489C (en) 2005-01-11
JPH03115232A (en) 1991-05-16
NO902986L (en) 1991-01-07
DE59008695D1 (en) 1995-04-20
GR3015580T3 (en) 1995-06-30
NO179247B (en) 1996-05-28
CA2020489A1 (en) 1991-01-06
RU2060246C1 (en) 1996-05-20
ES2069677T3 (en) 1995-05-16
CS277109B6 (en) 1992-11-18
ATE119783T1 (en) 1995-04-15
HU904104D0 (en) 1990-12-28

Similar Documents

Publication Publication Date Title
EP0108638B1 (en) X-ray contrast agents
AU2008273037B2 (en) Contrast agents
US5698739A (en) Carboxamide non-ionic contrast media
AU643447B2 (en) Novel carboxamide non-ionic contrast media
KR19990022943A (en) Formyl derivatives as nonionic contrast agents
JP5248330B2 (en) Contrast agent
US8323619B2 (en) Contrast agents
EP2231200A1 (en) Contrast agents
ES2390494T3 (en) Contrast agents
JPS63500522A (en) Nonionic polyol contrast media from ionic contrast media
US5356613A (en) X-ray contrast agents, compositions and methods
WO2008123779A1 (en) Trisubstituted triazamacrocycli c compounds and their use as contrast agents
WO2009047315A1 (en) Contrast agents
WO2009047316A1 (en) Contrast agents
US7662859B2 (en) Contrast agents
EP0647618A1 (en) New non ionic iodine-containing dimers useful as x-ray contrast agents, method for the preparation thereof, and galenical compositions containing them
EP2200655B1 (en) Contrast agents
DD296419A5 (en) NEW NON-IONIC CARBOXAMIDE CONTRAST
EP2245003A2 (en) Contrast agents
GB2457358A (en) X-Ray contrast agents comprising three iodinated phenyl groups
MXPA97010220A (en) Derivatives of formilo as means of contrast noioni

Legal Events

Date Code Title Description
PC Assignment registered

Owner name: DR MILOS SOVAK

Free format text: FORMER OWNER WAS: SCHERING AKTIENGESELLSCHAFT